TLC (Taiwan Liposome Company), dedicated to the development of novel nanomedicines, announced that it has signed an agreement with Jixi Biotechnology Partners to form a joint venture in TLC Biopharmaceuticals Limited with the purpose to conduct clinical studies, register, and commercialize TLC’s pipeline.
The new partnership’s efforts will take place pursuant to recent reforms by the China Food and Drug Administration office (CFDA), which include initiatives designed to accelerate drug approvals and encourage innovation, including greater alignment of China’s review process with that of the US and the EU.
“We are delighted to be collaborating with Jixi Biotechnology, which has resources and networks in regulatory affairs and commercialization in this critically important territory,” says TLC President George Yeh. “This is an important step forward in our support toward China’s ongoing healthcare reforms and is a milestone in our efforts to address the needs of patients worldwide.”
TLC’s pipeline focuses on the pain management, ophthalmology, and oncology spaces. TLC has two approved products in oncology which are branded generics or off-patent drugs, a fast-growing sector in China.
TLC is a clinical-stage specialty pharmaceutical company dedicated to the research and development of best-in-class novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™).